AngioDynamics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Shareholders held on November 10, 2025. AngioDynamics, Inc. (NASDAQ: ANGO) is a Delaware corporation incorporated in 1986, with principal executive offices in Latham, New York. The filing details the outcomes of shareholder votes on director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The document serves to disclose the results of the shareholder vote rather than operational or financial shifts compared to prior periods.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future financial performance. It confirms the successful ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending May 31, 2026. Additionally, the advisory proposal to approve executive compensation was passed by shareholders.
Key Facts for Investor Verification
- Director Elections: James C. Clemmer and Michael E. Tarnoff, MD were elected as Class I directors to serve until the 2028 Annual Meeting.
- Auditor Ratification: Shareholders approved the appointment of Deloitte & Touche LLP with 35,727,186 votes for approval versus 156,899 against.
- Executive Compensation: The advisory vote on executive compensation received 28,357,782 votes for approval, with 2,057,982 votes against.
- Voting Participation: Significant broker non-votes (5,462,943) were recorded for the director elections and executive compensation proposal.